Dr Giulio Kleiner

The plasmablast response to SARS-CoV-2 mRNA vaccination is dominated by non-neutralizing 1 antibodies and targets both the NTD and the RBD 2

F. Krammer, G. Bajic, A. Ellebedy, 2021 .